Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

T-small cell disorders.

E H Westin¹, D L Longo

¹National Institute on Aging/NIH, 5600 Nathan Shock Drive, Baltimore, MD 21224-6825, USA.

Current Treatment Options in Oncology

|June 12, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Endothelial cells require functional FLVCR1a during developmental and adult angiogenesis.

Angiogenesis·2023

Same author

Complete on/off responsive ParaCEST MRI contrast agents for copper and zinc.

Dalton transactions (Cambridge, England : 2003)·2018

Same author

Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.

Clinical pharmacology and therapeutics·2016

Same author

A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.

Leukemia·2014

Same author

p52-Independent nuclear translocation of RelB promotes LPS-induced attachment.

Biochemical and biophysical research communications·2009

Same author

Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model.

Leukemia·2007

Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026

Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026

Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026

Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026

Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026

Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026

See all related articles

Small T-cell lymphoproliferative disorders, including T-cell prolymphocytic leukemia and mycosis fungoides, are rare and often incurable. New therapies offer palliation, but research requires international cooperation for effective treatment trials.

Area of Science:

Hematology
Oncology

Background:

Small T-cell lymphoproliferative disorders constitute a rare subset (<2%) of all lymphoproliferative conditions.
Key entities include T-cell prolymphocytic leukemia, T-cell granular lymphocytic leukemia, and mycosis fungoides/Sézary syndrome.

Purpose of the Study:

To review the characteristics and treatment challenges of rare small T-cell lymphoproliferative disorders.
To highlight emerging therapeutic strategies and the need for collaborative research.

Main Methods:

Literature review and synthesis of current knowledge on T-cell lymphoproliferative disorders.
Analysis of treatment modalities and their efficacy.

Main Results:

Mycosis fungoides is the most common, with an indolent course, while T-cell prolymphocytic leukemias are typically refractory to treatment with poor prognosis.

Related Experiment Videos

While generally incurable, palliation can be achieved through radiation, chemotherapy, and biologics.

Conclusions:

Novel agents like nucleosides, interferon, monoclonal antibodies, and vitamin A derivatives offer improved palliation.
The rarity of these diseases necessitates national and international collaboration for large-scale clinical trials to accelerate treatment advancements.